Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Ceralasertib Administered to Japanese Patients With Advanced Solid Malignancies

NCT05469919 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05469919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05469919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Ceralasertib Administered to Japanese Patients With Advanced Solid Malignancies
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
June 9, 2022
Completion date
March 12, 2024
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies